(NASDAQ: ALT) Altimmune's forecast annual revenue growth rate of 2,271.26% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Altimmune's revenue in 2025 is $15,000.On average, 1 Wall Street analysts forecast ALT's revenue for 2025 to be $16,221,394,600, with the lowest ALT revenue forecast at $16,221,394,600, and the highest ALT revenue forecast at $16,221,394,600. On average, 1 Wall Street analysts forecast ALT's revenue for 2026 to be $16,221,394,600, with the lowest ALT revenue forecast at $16,221,394,600, and the highest ALT revenue forecast at $16,221,394,600.
In 2027, ALT is forecast to generate $6,717,685,039 in revenue, with the lowest revenue forecast at $3,000,958,001 and the highest revenue forecast at $10,434,412,076.